Kura Oncology, INC. (KURA) — 8-K Filings

8-K Filings (19)

• Kura Oncology Files 8-K: Other Events — Dec 2, 2025 Risk: medium
  Kura Oncology, Inc. filed an 8-K on December 2, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, d
• 8-K Filing — Nov 13, 2025
• Kura Oncology Files 8-K — Oct 24, 2025 Risk: medium
  Kura Oncology, Inc. filed an 8-K on October 24, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, d
• Kura Oncology Files 8-K — Oct 16, 2025 Risk: medium
  Kura Oncology, Inc. filed an 8-K on October 16, 2025, reporting an event that occurred on October 15, 2025. The filing is categorized under 'Other Events' and '
• Kura Oncology Enters Material Definitive Agreement — Jul 1, 2025 Risk: medium
  On June 27, 2025, Kura Oncology, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counte
• Kura Oncology Files 8-K — Jun 18, 2025 Risk: medium
  Kura Oncology, Inc. filed an 8-K on June 18, 2025, reporting an event that occurred on June 12, 2025. The filing pertains to 'Other Events' and 'Financial State
• Kura Oncology Files 8-K on Officer/Director Changes — Jun 6, 2025 Risk: medium
  Kura Oncology, Inc. filed an 8-K on June 6, 2025, reporting on several key events that occurred on June 5, 2025. These include the departure of directors or cer
• Kura Oncology Files 8-K — Jun 3, 2025 Risk: low
  Kura Oncology, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements as of June 1, 2025. The filing does not contain specific detai
• Kura Oncology Files 8-K for Operations Update — Feb 26, 2025 Risk: low
  Kura Oncology, Inc. filed an 8-K on February 26, 2025, to report on its results of operations and financial condition. The filing does not contain specific fina
• Kura Oncology Files 8-K — Feb 5, 2025 Risk: low
  Kura Oncology, Inc. filed an 8-K on February 5, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is located at 1273
• Kura Oncology Enters Material Definitive Agreement — Jan 14, 2025 Risk: medium
  On January 13, 2025, Kura Oncology, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The spe
• Kura Oncology Announces Board and Executive Changes — Jan 6, 2025 Risk: low
  Kura Oncology, Inc. announced on January 1, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected n
• Kura Oncology Files 8-K — Dec 20, 2024 Risk: medium
  Kura Oncology, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 16, 2024. The filing is a current report and does not specif
• Kura Oncology Enters Material Definitive Agreement — Nov 20, 2024 Risk: medium
  On November 20, 2024, Kura Oncology, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offic
• Kura Oncology Appoints New CMO, CSO, and Directors — Sep 17, 2024 Risk: medium
  Kura Oncology, Inc. announced on September 13, 2024, changes in its executive team and board of directors. Specifically, Dr. Michael J. Grey was appointed as Ch
• Kura Oncology Announces Board, Officer, and Compensation Changes — Jun 7, 2024 Risk: medium
  Kura Oncology, Inc. announced on June 5, 2024, a series of significant corporate changes. These include the election of new directors, the appointment of new of
• Menarini Group to Acquire Kura Oncology for $1.1 Billion — May 24, 2024 Risk: medium
  Kura Oncology, Inc. announced on May 24, 2024, that it has entered into a definitive agreement to be acquired by Menarini Group. The transaction is valued at ap
• Kura Oncology Files 8-K: Corporate Info Update, Nasdaq Listing Confirmed — Jan 30, 2024
  Kura Oncology, Inc. filed an 8-K on January 30, 2024, to update its corporate information, including its address at 12730 High Bluff Drive, Suite 400, San Diego
• Kura Oncology Reports Material Agreement & Unregistered Equity Sales — Jan 26, 2024
  Kura Oncology, Inc. filed an 8-K on January 26, 2024, reporting an event on January 24, 2024, concerning an entry into a material definitive agreement and unreg

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX